Wall Street brokerages predict that Sierra Oncology Inc (NASDAQ:SRRA) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks. Zero analysts have provided estimates for Sierra Oncology’s earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.17). Sierra Oncology reported earnings of ($0.20) per share in the same quarter last year, which would indicate a negative year over year growth rate of 5%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.80) to ($0.73). For the next year, analysts expect that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.95) to ($0.66). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.03).
Several brokerages have recently weighed in on SRRA. Zacks Investment Research raised shares of Sierra Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st. ValuEngine downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd.
Shares of SRRA opened at $1.63 on Monday. Sierra Oncology has a twelve month low of $1.48 and a twelve month high of $4.09. The firm has a market capitalization of $121.22 million, a PE ratio of -1.94 and a beta of 1.73. The company has a current ratio of 14.68, a quick ratio of 14.68 and a debt-to-equity ratio of 0.05.
Several institutional investors and hedge funds have recently made changes to their positions in SRRA. UBS Group AG purchased a new stake in shares of Sierra Oncology in the first quarter valued at $111,000. Acadian Asset Management LLC raised its stake in shares of Sierra Oncology by 156.9% in the second quarter. Acadian Asset Management LLC now owns 315,627 shares of the biotechnology company’s stock valued at $934,000 after acquiring an additional 192,757 shares during the period. Algert Global LLC raised its stake in shares of Sierra Oncology by 512.2% in the second quarter. Algert Global LLC now owns 143,991 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 120,471 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Sierra Oncology by 25.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,950 shares of the biotechnology company’s stock valued at $305,000 after acquiring an additional 20,950 shares during the period. Finally, Spark Investment Management LLC raised its stake in shares of Sierra Oncology by 35.7% in the second quarter. Spark Investment Management LLC now owns 330,900 shares of the biotechnology company’s stock valued at $979,000 after acquiring an additional 87,100 shares during the period. 65.47% of the stock is currently owned by institutional investors and hedge funds.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
See Also: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.